XML 76 R65.htm IDEA: XBRL DOCUMENT v3.20.2
Note 13 - Segment Information - Operating Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Total revenues [1] $ 31,860 $ 25,536 $ 61,801 $ 51,824
Gross profit 21,285 15,586 41,625 31,790
Reconciling items [2] (18,901) (11,812) (38,487) (22,591)
Earnings before income taxes 2,384 3,774 3,138 9,199
Corporate, Non-Segment [Member]        
Total revenues 0 896 [1]   2,213 [1]
Gross profit 83 85 64 412
Sterilization and Disinfection Control [Member] | Operating Segments [Member]        
Total revenues [1] 11,552 12,094 24,619 24,204
Gross profit 8,770 8,723 18,790 17,233
Instruments [Member] | Operating Segments [Member]        
Total revenues [1] 7,558 8,960 15,238 18,504
Gross profit 4,852 5,557 9,541 11,639
Biopharmaceutical Development [Member] | Operating Segments [Member]        
Total revenues 9,131 [1] 0 15,080 [1]  
Gross profit 6,212   10,678  
Cold Chain Monitoring [Member] | Operating Segments [Member]        
Total revenues [1] 3,619 3,586 6,864 6,903
Gross profit $ 1,368 $ 1,221 $ 2,552 $ 2,506
[1] Intersegment revenues are not significant and are eliminated to arrive at consolidated totals.
[2] Reconciling items include selling, general and administrative, research and development, interest expense and amortization of debt discount, and other (income) expenses.